Last10K.com

Oncotelic Therapeutics, Inc. (OTLC) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

Oncotelic Therapeutics, Inc.

CIK: 908259 Ticker: OTLC
Cover - shares
3 Months Ended
Mar. 31, 2022
May 16, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateMar. 31, 2022 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--12-31 
Entity File Number000-21990 
Entity Registrant NameOncotelicTherapeutics, Inc. 
Entity Central Index Key0000908259 
Entity Tax Identification Number13-3679168 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One29397 Agoura Road 
Entity Address, Address Line TwoSuite 107 
Entity Address, City or TownAgoura Hills 
Entity Address, State or ProvinceCA 
Entity Address, Postal Zip Code91301 
City Area Code(650) 
Local Phone Number635-7000 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 378,630,104

View differences made from one quarter to another to evaluate Oncotelic Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncotelic Therapeutics, Inc..

Continue

Assess how Oncotelic Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Consolidated Balance Sheets (Unaudited)
Consolidated Balance Sheets (Unaudited) (Parenthetical)
Consolidated Statement Of Stockholders' Equity (Unaudited)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited))
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Tables)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Convertible Debentures, Notes And Other Debt
Convertible Debentures, Notes And Other Debt (Details Narrative)
Convertible Debentures, Notes And Other Debt (Tables)
Description Of Business And Basis Of Presentation
Description Of Business And Basis Of Presentation (Details Narrative)
Equity Purchase Agreement And Registration Rights Agreement
Equity Purchase Agreement And Registration Rights Agreement (Details Narrative)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Details Narrative)
Goodwill And Intangible Assets (Tables)
Income Taxes
Income Taxes (Details Narrative)
Joint Venture With Gmp Affiliates
Joint Venture With Gmp Affiliates (Details Narrative)
Private Placement And Jh Darbie Financing
Private Placement And Jh Darbie Financing (Details Narrative)
Private Placement And Jh Darbie Financing (Tables)
Related Party Transactions
Related Party Transactions (Details Narrative)
Related Party Transactions (Tables)
Schedule Of Accounts Payable And Accrued Expenses (Details)
Schedule Of Amortization Of Expense For Intangible Assets (Details)
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Black Scholes Valuation Allowance Model Of Warrants (Details)
Schedule Of Convertible Notes (Details)
Schedule Of Convertible Notes, Net Of Discount (Details)
Schedule Of Fair Value Warrants Estimated Using Black Scholes Valuation Model (Details)
Schedule Of Funds Received Under The Subscription Agreement (Details)
Schedule Of Intangible Assets (Details)
Schedule Of Options To Purchase Shares Of Common Stock Outstanding And Exercisable (Details)
Schedule Of Related Party License Agreement (Details)
Schedule Of Short-Term Loans (Details)
Schedule Of Warrants Outstanding And Exercisable (Details)
Stock-Based Compensation
Stock-Based Compensation (Details Narrative)
Stock-Based Compensation (Tables)
Stockholders??? Equity
Stockholders??? Equity (Details Narrative)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Changes In Fair Value Of Derivative Liabilities (Details)
Summary Of Estimate Fair Value Of Derivative Liabilities (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)

Material Contracts, Statements, Certifications & more

Oncotelic Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: OTLC
CIK: 908259
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-014681
Submitted to the SEC: Mon May 23 2022 6:20:59 AM EST
Accepted by the SEC: Mon May 23 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/otlc/0001493152-22-014681.htm